Management of Frontotemporal Dementia

Assessment and Diagnosis

A comprehensive evaluation is essential to accurately diagnose frontotemporal dementia (FTD) and distinguish it from psychiatric disorders, requiring expertise from both neurological and psychiatric perspectives 2, 3
Structured psychiatric symptom rating scales may be helpful in differentiating behavioral variant FTD (bvFTD) from primary psychiatric disorders, though their systematic use requires further research 3
Neurological examination should identify motor signs that may be associated with FTD or FTD-related disorders, such as parkinsonism, which can help differentiate from psychiatric conditions 3

Person-centered, non-pharmacological approaches should form the foundation of FTD management, focusing on structured individualized activities tailored to patient interests and abilities, establishment of predictable daily routines, communication interventions, and occupational therapy guided by the person-environment-occupation model 1
The DICE approach (Describe, Investigate, Create, Evaluate) is recommended for managing neuropsychiatric symptoms, including identifying potential triggers or contributors 3 and developing and implementing a treatment plan 1, with assessment of effectiveness and adjustment as needed 4

Selective serotonin reuptake inhibitors (SSRIs) are recommended as first-line pharmacological treatment for disinhibition, compulsive behaviors, and inappropriate social conduct in FTD patients 1
Atypical antipsychotics may be considered for severe behavioral disturbances but should be used with caution and only when non-pharmacological approaches and SSRIs have failed, due to risks including worsening parkinsonism 1
Cholinesterase inhibitors and memantine have not shown consistent positive effects in FTD and are generally not recommended 1

A multidisciplinary team approach is essential, involving neurologists, psychiatrists, speech therapists, occupational therapists, and caregivers 1
Regular support and education for caregivers is critical throughout the disease course, as caregivers of individuals with FTD experience high levels of distress and depression 1
Anticipatory guidance should prepare caregivers for disease progression and changing needs 1

Relying primarily on pharmacological approaches when non-pharmacological strategies should be first-line 1
Using cholinesterase inhibitors or memantine based on experience with Alzheimer's disease, despite lack of evidence for efficacy in FTD 1
Inadequate caregiver education and support, which can lead to poor management outcomes 1
Using antipsychotics without careful monitoring for worsening parkinsonism or other adverse effects 1